Who Generates More Revenue? ACADIA Pharmaceuticals Inc. or Evotec SE

Evotec SE leads in revenue, but ACADIA shows rapid growth.

__timestamp	ACADIA Pharmaceuticals Inc.	Evotec SE
Wednesday, January 1, 2014	120000	89496000
Thursday, January 1, 2015	61000	127677000
Friday, January 1, 2016	17331000	164507000
Sunday, January 1, 2017	124901000	257630000
Monday, January 1, 2018	223807000	375405000
Tuesday, January 1, 2019	339076000	446437000
Wednesday, January 1, 2020	441755000	500924000
Friday, January 1, 2021	484145000	618034000
Saturday, January 1, 2022	517235000	751448000
Sunday, January 1, 2023	726437000	781426000

Igniting the spark of knowledge

Revenue Race: ACADIA Pharmaceuticals Inc. vs. Evotec SE

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of success. Over the past decade, ACADIA Pharmaceuticals Inc. and Evotec SE have been vying for dominance. From 2014 to 2023, Evotec SE consistently outpaced ACADIA in revenue, with a notable 2023 figure where Evotec's revenue was approximately 7% higher than ACADIA's. This trend highlights Evotec's robust growth strategy, as it maintained a lead in revenue generation for most of the years. However, ACADIA showed remarkable progress, especially from 2018 onwards, with a revenue increase of over 200% by 2023. This surge reflects ACADIA's strategic advancements and market penetration. As both companies continue to innovate, the revenue race remains a fascinating aspect of their financial narratives.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025